文献速递癫痫神经重症与神经感染

持续静脉麻醉药物治疗难治性癫痫持续状态:系统综述

Treatment of Refractory Status Epilepticus With Continuous Intravenous Anesthetic Drugs: A Systematic Review.
PubMed 文献 · JAMA Neurol · 2024-01-01

该系统综述纳入66项研究共1637例患者,比较不同持续静脉麻醉药物(CIVAD)治疗难治性癫痫持续状态(RSE)的结局。非癫痫相关RSE较癫痫相关RSE的CIVAD替换率更高(50.0% vs 25.6%,OR 3.11)且死亡率更高(43.2% vs 11.1%,OR 17.0)。CIVAD选择和脑电图监测类型不是死亡预测因素,总体数据异质性限制了对最佳初始CIVAD的确定结论。

要点

  • 非癫痫相关RSE较癫痫相关RSE的CIVAD替换率更高(50.0% vs 25.6%,OR 3.11)且死亡率更高(43.2% vs 11.1%,OR 17.0)。
  • 癫痫发作抑制与死亡率相关(OR 7.72),但仅小部分亚组可分析(发作抑制22例中17例 vs 爆发抑制98例中25例)。
  • CIVAD选择和脑电图监测类型不是死亡预测因素;较早发表年份与死亡率相关,但聚类调整后未达统计学显著。

核心结论

  • 癫痫相关RSE与其他病因RSE相比死亡率更低。
  • 观察到死亡率随时间下降的趋势,可能提示神经重症监护进展的效果。
  • 总体数据异质性大,限制了对RSE最佳初始CIVAD选择的确定结论。

研究设计与样本

  • 系统综述,遵循PRISMA指南,检索Embase、MEDLINE、PubMed和Web of Science(1994年1月至2023年6月)及手动检索,纳入同行评议研究,要求至少5例患者且至少1例年龄大于12岁,经苯二氮䓬类和至少一种标准抗癫痫药物治疗仍难治,并接受持续输注咪达唑仑、氯胺酮、丙泊酚、戊巴比妥或硫喷妥钠治疗。
  • 共纳入66项研究,1637例患者。

主要发现

  • 不同CIVAD组在短期失败、低血压和治疗期间CIVAD替换方面存在显著差异。
  • 非癫痫相关RSE较癫痫相关RSE的CIVAD替换率更高(60/120 [50.0%] vs 11/43 [25.6%];OR 3.11;95% CI 1.44-7.11;P = .006)。
  • 非癫痫相关RSE较癫痫相关RSE的死亡率更高(98/227 [43.2%] vs 7/63 [11.1%];OR 17.0;95% CI 4.71-109.35;P < .001)。
  • 癫痫发作抑制与死亡率相关(OR 7.72;95% CI 1.77-39.23;P = .005),但仅小亚组可分析(发作抑制:3篇文献中17/22 [77.3%] vs 爆发抑制:12篇文献中25/98 [25.5%])。
  • CIVAD选择和脑电图监测类型不是死亡预测因素;较早发表年份与死亡率相关,但聚类调整标准误后不再具有统计学显著性。

局限性

  • 总体数据异质性大,限制了对RSE最佳初始CIVAD选择的确定结论。
  • 癫痫发作抑制与死亡率相关的分析仅基于小亚组(发作抑制22例来自3篇文献,爆发抑制98例来自12篇文献)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Multiple continuous intravenous anesthetic drugs (CIVADs) are available for the treatment of refractory status epilepticus (RSE). There is a paucity of data comparing the different types of CIVADs used for RSE. OBJECTIVE: To systematically review and compare outcome measures associated with the initial CIVAD choice in RSE in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. EVIDENCE REVIEW: Data sources included English and non-English articles using Embase, MEDLINE, PubMed, and Web of Science (January 1994-June 2023) as well as manual search. Study selection included peer-reviewed studies of 5 or more patients and at least 1 patient older than 12 years with status epilepticus refractory to a benzodiazepine and at least 1 standard antiseizure medication, treated with continuously infused midazolam, ketamine, propofol, pentobarbital, or thiopental. Independent extraction of articles was performed using prespecified data items. The association between outcome variables and CIVAD was examined with an analysis of variance or χ2 test where appropriate. Binary logistic regressions were used to examine the association between outcome variables and CIVAD with etiology, change in mortality over time, electroencephalography (EEG) monitoring (continuous vs intermittent), and treatment goal (seizure vs burst suppression) included as covariates. Risk of bias was addressed by listing the population and type of each study. FINDINGS: A total of 66 studies with 1637 patients were included. Significant differences among CIVAD groups in short-term failure, hypotension, and CIVAD substitution during treatment were observed. Non-epilepsy-related RSE (vs epilepsy-related RSE) was associated with a higher rate of CIVAD substitution (60 of 120 [50.0%] vs 11 of 43 [25.6%]; odds ratio [OR], 3.11; 95% CI, 1.44-7.11; P = .006) and mortality (98 of 227 [43.2%] vs 7 of 63 [11.1%]; OR, 17.0; 95% CI, 4.71-109.35; P < .001). Seizure suppression was associated with mortality (OR, 7.72; 95% CI, 1.77-39.23; P = .005), but only a small subgroup was available for analysis (seizure suppression: 17 of 22 [77.3%] from 3 publications vs burst suppression: 25 of 98 [25.5%] from 12 publications). CIVAD choice and EEG type were not predictors of mortality. Earlier publication year was associated with mortality, although the observation was no longer statistically significant after adjusting SEs for clustering. CONCLUSIONS AND RELEVANCE: Epilepsy-related RSE was associated with lower mortality compared with other RSE etiologies. A trend of decreasing mortality over time was observed, which may suggest an effect of advances in neurocritical care. The overall data are heterogeneous, which limits definitive conclusions on the choice of optimal initial CIVAD in RSE treatment.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Au YK, Kananeh MF, Rahangdale R, et al. Treatment of Refractory Status Epilepticus With Continuous Intravenous Anesthetic Drugs: A Systematic Review. JAMA Neurol. 2024. PMID: 38466294. doi:10.1001/jamaneurol.2024.0108

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。